Boenning & Scattergood Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Neutral
ONXX Hot Sheet
Rating Summary:10 Buy, 3 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Boenning & Scattergood initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Neutral.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
You May Also Be Interested In
- Bernstein Starts Onyx Pharmaceuticals (ONXX) at Outperform
- Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
Create E-mail Alert Related Categories
New CoverageRelated Entities
Boenning & ScattergoodSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
